TYMS Amplification

CI-VAR-00000213Explore in graph →CIViC 379

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
TYMS Amplification	Pemetrexed	Predictive	B	Supports Resistance	3	accepted	EID903 TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines. PMID 23645741 · Kasai et al., 2013 · Open in CIViC	civic
Malignant Colorectal Neoplasm2
TYMS Amplification	5-Fluorouracil/Salicylic Acid Topical Solution	Predictive	B	Supports Resistance	3	submitted	EID12097 Genomic DNA from liver metastases of four different colorectal cancer patients who had previously undergone 5-FU-based adjuvant chemotherapy was evaluated using digital karyotyping. TYMS amplification… (full text at CIViC) PMID 14970324 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.